MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ
2.190
+0.120
+5.80%
After Hours: 2.176 -0.014 -0.64% 17:32 07/06 EDT
OPEN
2.060
PREV CLOSE
2.070
HIGH
2.270
LOW
2.026
VOLUME
1.39M
TURNOVER
--
52 WEEK HIGH
2.660
52 WEEK LOW
0.4399
MARKET CAP
294.69M
P/E (TTM)
-1.4686
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALXO last week (0629-0703)?
Weekly Report · 12h ago
ALX Oncology grants General Counsel Listgarten option for 500,000 shares at $2.20 each
PUBT · 6d ago
ALX ONCOLOGY REPORTS INDUCEMENT GRANT AS PERMITTED BY THE NASDAQ LISTING RULES
Reuters · 6d ago
ALX Oncology Appoints New Chairman Amid Leadership Changes
TipRanks · 6d ago
ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
Benzinga · 6d ago
ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds
TipRanks · 6d ago
ALX Oncology names Scott Garland board chairman, replacing co-founder Corey Goodman
PUBT · 6d ago
ALX ONCOLOGY APPOINTS SCOTT GARLAND AS CHAIRMAN OF THE BOARD AND MICHAEL LISTGARTEN AS GENERAL COUNSEL
Reuters · 6d ago
More
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Webull offers ALX Oncology Holdings Inc stock information, including NASDAQ: ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.